Volume 12, Issue 2 (2022)                   JMBS 2022, 12(2): 91-102 | Back to browse issues page

XML Persian Abstract Print


1- masters student, university of guilan
2- Associate Professor in Biochemistry, Faculty of Sciences, University of Guilan, Department of Biology, Faculty of Basic Sciences, University of Guilan, Rasht, Iran, Postal code:4193833697 , h.ghafoori@guilan.ac.ir
3- Associate Professor in Chemistry, Faculty of Sciences, University of Guilan
4- Ph.D. student, University of Guilan
Abstract:   (1355 Views)
Aim: During the uncontrolled development of cells in the body, a subset of neoplasms or tumors is formed, the abnormal proliferation of these cells leads to the formation of a mass and eventually cancer. This mass can spread throughout the body. Thus, inhibiting the abnormal growth of cancer cells will have a significant effect on preventing the spread of cancerous tumors and improving the disease. Therefore, in the present study, a new sulfonamide derivative was designed and synthesized (HB20) and its anti-cancer effects on human breast cancer cell line (MCF-7) were investigated.
Materials and Methods: For the synthesis of a sulfonamide derivative (HB20), dcriptiazonium salt was first made using a sulfamethoxazole base compound and then combined with a pyrimidine coupling agent. Concentrations of a new synthetic compound (HB20) against Cells (MCF-7) were used. MTT assay was also performed to measure survival and cell proliferation.
Results: The synthesized compound structure was confirmed by spectral analysis, such as FT- IR, and NMR. Also, Survival in MCF-7 cells treated with a synthetic compound (HB20) was significantly reduced compared to the control group (untreated). HB20 inhibits the proliferation of MCF-7 cancer cells with an IC50 value of 75/23 μg/ml.
Conclusion: The new sulfonamide derivative (HB20) has the potential to inhibit proliferation and anti-cancer properties in the cell line (MCF-7).
Full-Text [PDF 590 kb]   (708 Downloads)    
Article Type: Original Research | Subject: Pharmaceutical Biotechnology
Received: 2020/08/17 | Accepted: 2021/02/3 | Published: 2022/01/30

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.